The FDA has approved Protein Sciences Corporation’s vaccine Flublok for the prevention of seasonal influenza in adults 18 to 49 years of age. Diamyd Medical holds about 8 percent of the shares in Protein Sciences Corporation.
Flublok is a recombinant protein-based seasonal influenza vaccine and the first influenza vaccine manufactured using recombinant technology that has received marketing approval by the FDA. Protein Sciences Corporation is planning to have a limited launch of the product in February 2013 with the full launch occurring in time for the 2013/14 influenza season.